Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer-Reference-Cited by-同舟云学术

Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer

Published:2023-12 Issue: Volume: Page:
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Bischoff Philip,Reck Martin,Overbeck Tobias,Christopoulos Petros,Rittmeyer Achim,Lüders Heike,Kollmeier Jens,Kulhavy Jonas,Kemper Marcel,Reinmuth Niels,Röper Julia,Janning Melanie,Sommer Linna,Aguinarte Lukas,Koch Myriam,Wiesweg Marcel,Wesseler Claas,Waller Cornelius F.,Kauffmann-Guerrero Diego,Stenzinger Albrecht,Stephan-Falkenau Susann,Trautmann Marcel,Lassmann Silke,Tiemann Markus,Klauschen Frederick,Sebastian Martin,Griesinger Frank,Wolf Jürgen,Loges Sonja,Frost Nikolaj^ORCID,Hilbrandt Moritz,Süptitz Juliane,Grah Christian,Velthaus Janna-Lisa,Kopp Hans-Georg,Schmidt Bernd,Horter Susanne,Keymel Stefanie,Aydilek Enver,Tritchkova Guergana,Raspe Matthias,Papić Dražen,Florian Stefan,Horst David,Wild Peter J.,Thomas Michael,Grohé Christian,Bleckmann Annalen,Wermke Martin,Hummel Horst-Dieter,Stratmann Jan,Schütte Wolfgang

Funder

German Cancer Aid

Berlin Institute of Health at Charité

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference46 articles.

1. The effect of advances in lung-cancer treatment on population mortality;Howlader;N Engl J Med,2020

2. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

3. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater;Reck;J Clin Oncol,2019

4. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >/= 50;Reck;J Clin Oncol,2021

5. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC;Herbst;N Engl J Med,2020

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms;Die Onkologie;2024-08-15

2. Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma;PLOS ONE;2024-07-22

3. Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer;Clinical and Experimental Medicine;2024-07-18

4. KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma;British Journal of Cancer;2024-06-12

5. Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations;American Society of Clinical Oncology Educational Book;2024-06